Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To explore the effect of magnetic iron nanoparticles ( Fe₃O₄- MNP) in combination with arsenic trioxide and adriamycin on apoptosis and autophagy of Raji cells, a non-Hodgkin's lymphoma (NHL) cell line.
Methods: The growth inhibition rate of Raji cells was analyzed by MTT assay, the cells apoptosis and intracellular concentration of ADM were determined by flow cytometry (FCM), the expression levels of apoptosis-related proteins such as BCL-2, NFκB, Survivin, BAX, P53, and Caspase-3, and related to autophagy-proteins, such as LC3, Beclin-1, and P62/SQSTM1 were detected by Western blot.
Results: The growth inhibition of Raji cells in the group of ADM + As₂O₃were higher than that in the group of ADM or As₂O₃alone, however, lower than that in the group of Fe₃O₄- MNP combined with ADM and As₂O₃(ADM+As₂O₃+ MNP) (P < 0.05). The apoptotic rate and accumulation of intracellular ADM in the group of Fe₃O₄- MNP combined with ADM and As₂O₃were significantly higher than those in control, ADM, As₂O₃, and ADM plus As₂O₃groups (P < 0.05). The upregulation of BAX, P53 and Caspase-3 expression and the down regulation of BCL-2, NFκB, and Survivin expression at protein level were more remarkable in the group of ADM+As₂O₃ + MNP, compared with the other groups (P < 0.05). Moreover, the expressions of LC3 and Beclin-1 proteins in the group of ADM+As₂O₃+ MNP were higher, while the expression of P62/SQSTM1 was lower than that in other groups (P < 0.05).
Conclusion: The Fe3O4 - MNP combined with ADM and As₂O₃can increase the antitumor efficacy on Raji cells by promoting apoptosis and inducing autophagy. It would be a promising strategy for malignant lymphoma therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7534/j.issn.1009-2137.2015.05.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mathematical model suggests current CAR-macrophage dosage is efficient to low pre-infusion tumour burden but refractory to high tumour burden.
J Theor Biol
September 2025
Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China. Electronic address:
Chimeric antigen receptor (CAR)-macrophage therapy is a promising approach for tumour treatment due to antigen-specific phagocytosis and tumour clearance. However, the precise impact of tumour burden, dose and dosing regimens on therapeutic outcomes remains poorly understood. We developed ordinary differential equation (ODE) mathematical modelling and utilised parameter inference to analyse in vitro FACS-based phagocytosis assay data testing CD19-positive Raji tumour cell against CAR-macrophage, and revealed that phagocytosing efficiency of CAR-macrophage increases but saturates as both Raji cell and CAR-macrophage concentrations increase.
View Article and Find Full Text PDFGalangin and 1'-Acetoxychavicol Acetate from Galangal () Suppress Lymphoma Growth via c-Myc Downregulation and Apoptosis Induction.
Biology (Basel)
August 2025
Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
The c-Myc protein, a key regulator of cell proliferation, growth, and apoptosis in B-cell lymphocytes, is frequently dysregulated in Burkitt's lymphoma. Zingiberaceae plants-galangal (), black turmeric (), black ginger (), phlai lueang (), and phlai dum ()-are traditionally used as herbal remedies and may serve as natural anti-lymphoma agents. In this study, extracts from these five plants were screened for cytotoxicity against Raji and Daudi lymphoma cell lines and compared with their effects on normal peripheral blood mononuclear cells (PBMCs).
View Article and Find Full Text PDFImproving transport efficiency for large human cells for enabling accurate determination of cellular nanoparticle uptake via SC-ICP-TOF-MS.
Talanta
August 2025
Ghent University, Department of Chemistry, Atomic & Mass Spectrometry - A&MS Research Group, Campus Sterre, Krijgslaan 281-S12, 9000, Ghent, Belgium.
Single-cell inductively coupled plasma-mass spectrometry (SC-ICP-MS) provides high-throughput, quantitative information on nanoparticle (NP)-cell interaction, but its application to larger mammalian cells remains limited due to the low transport efficiency (TE) provided by commercially available introduction systems. In this study, we have addressed this challenge by working at a higher spray chamber temperature (150 °C), which led to a 81-fold increase in TE for A549 human lung carcinoma cells (measured size of ∼20 μm). This observation was also validated using other cell types with different sizes and morphologies, such as red blood cells (∼6 μm) and Raji cells (∼11 μm), for which respective TE improvements of 2.
View Article and Find Full Text PDFGenetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus.
Ann Rheum Dis
August 2025
Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address:
Objectives: Given the efficacy of B-cell depletion therapy in systemic lupus erythematosus (SLE) treatment and the capacity of engineered natural killer (NK) cells in B-cell elimination, we explored the potential of genetically modified NK cells to target CD19 for the treatment of SLE.
Methods: Peripheral blood-derived NK cells were engineered with CAR.CD19/interleukin (IL)-15 (XB-19.
Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles.
Exp Hematol Oncol
August 2025
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chimeric antigen receptor (CAR)-T-cell therapy has achieved remarkable clinical success in the treatment of B-cell malignancies; however, its efficacy can be limited by poor T-cell persistence and insufficient antitumor activity in certain cases. Moreover, interleukin-12 (IL-12) is a prominent agent in cancer immunotherapy, but its clinical application is constrained by severe toxicity associated with systemic exposure. In this study, we developed a novel cytokine delivery platform based on CAR target-modified cell-derived extracellular vesicles (EVs) that preferentially bind CAR-T cells to improve CAR-T-cell function.
View Article and Find Full Text PDF